title: How we diagnose and treat essential thrombocythaemia.
abstract: The approach to the diagnosis and management of essential thrombocythaemia (ET) is steadily changing, influenced by advances in molecular biology, data from clinical trials and retrospective analyses of patient cohorts. In the past decade options for clinical management largely remain unchanged, but who we treat, and with what target in mind, is evolving. A further area of change is recognition of symptoms that may be associated with ET, as well as other myeloproliferative neoplasms, and that potential options for their management are becoming available. Judicious and careful diagnosis is increasingly a fundamental key to successful management followed by cytoreductive therapy in a subset of patients. In this review we demonstrate our management strategies for ET using a case-based format.
authors.affiliation: Department of Haematology, Guy's & St Thomas' Hospitals NHS Foundation Trust, Guy's Hospital, London, UK.
authors.forename: Samah
authors.initials: S
authors.lastname: Alimam
authors.affiliation: Department of Cellular Pathology, Guy's & St Thomas' Hospitals NHS Foundation Trust, St Thomas' Hospital, London, UK.
authors.forename: Bridget S
authors.initials: BS
authors.lastname: Wilkins
authors.affiliation: Department of Haematology, Guy's & St Thomas' Hospitals NHS Foundation Trust, Guy's Hospital, London, UK.
authors.forename: Claire N
authors.initials: CN
authors.lastname: Harrison
mesh_terms: D002986:Clinical Trials as Topic; D006801:Humans; D013920:Thrombocythemia, Essential / Q000175:diagnosis* / Q000628:therapy
keywords: CALR; JAK2; essential thrombocythaemia; thrombocytosis